Go Deep
Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,445 | -6.9 | 2.17 | 0.47 | 341.43 |
Cyfuse Biomedical K.K. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 75,842,000.0 | 28,479,000.0 | 169,039,000.0 | 32,540,000.0 |
| Net Profit | -210,442,000.0 | -224,146,000.0 | -126,660,000.0 | -234,662,000.0 |
| EPS | — | -22.6 | — | — |
Cyfuse Biomedical K.K. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 230,999,000.0 | 54,446,000.0 | 61,112,000.0 | 374,477,000.0 |
| Net Profit | -763,843,000.0 | -872,238,000.0 | -589,211,000.0 | -473,962,000.0 |
| EPS | -86.8 | -108.3 | -75.4 | -177.7 |
Cyfuse Biomedical K.K. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 4,266,026,000.0 | 3,518,001,000.0 | 4,214,809,000.0 | 4,815,337,000.0 | — |
| Total Liabilities | 1,508,400,000.0 | 975,596,000.0 | 1,011,340,000.0 | 1,045,536,000.0 | — |
| Total Equity | 2,757,626,000.0 | 2,542,405,000.0 | 3,203,469,000.0 | 3,769,801,000.0 | — |
Owes vs Owns
Cyfuse Biomedical K.K. owed ¥0.33 for every ¥1 it owned in Jun 2026, up from ¥0.22 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.33× | 0.35× | 0.28× | 0.24× | 0.22× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cyfuse Biomedical K.K. Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 87.4%Inventory 2.1%Fixed assets (tangible) 4.8%Other assets 5.6%
How it's funded — Dec 2025
Short-term debt 15.7%Long-term debt 15.1%Payables 1.6%Other liabilities 3.0%Shareholders' equity 64.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3,726.5 | 3,052.6 | 3,873.8 | 4,437.3 |
| Receivables | 5.5 | 20.9 | 17.1 | 13.6 |
| Inventory | 88.7 | 55.6 | 46.0 | 40.4 |
| Fixed assets (tangible) | 203.3 | 192.5 | 223.0 | 244.5 |
| Intangible assets | 3.4 | 4.2 | 4.4 | 5.5 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 238.6 | 192.2 | 50.5 | 74.1 |
| Liabilities & equity | ||||
| Short-term debt | 669.7 | 525.8 | 568.0 | 545.1 |
| Long-term debt | 642.3 | 327.0 | 345.0 | 363.0 |
| Payables | 69.5 | 15.6 | 1.3 | 3.2 |
| Other liabilities | 126.9 | 107.2 | 97.1 | 134.2 |
| Shareholders' equity | 2,757.6 | 2,542.4 | 3,203.5 | 3,769.8 |
| Net tangible assets | 2,754.2 | 2,538.2 | 3,199.1 | 3,764.3 |
Cyfuse Biomedical K.K. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -534,793,000.0 | -760,553,000.0 | -562,296,000.0 | -403,596,000.0 | — |
| Investing Activities | -397,564,000.0 | -8,637,000.0 | -19,474,000.0 | -430,674,000.0 | — |
| Financing Activities | 1,256,323,000.0 | -52,012,000.0 | 18,236,000.0 | 2,658,538,000.0 | — |